GPHL gains clinical trial permission for class 1.1 new drug Ceftriamidine Sodium
2018-01-12 17:30:53 GPHL GPHL
On the evening of Jan. 1, GPHL announced that its Baiyunshan Pharmaceutical General Factory and Baiyunshan Chemical Pharmaceutical Factory have received permission from the China Food and Drug Administration to conduct clinical trials with their class 1.1 new drug Ceftriamidine Sodium and Ceftriamidine Sodium for Injection.
Ceftriamidine Sodium is the only new class 1.1 cephalosporin drug that has been allowed to be clinically trialed over the past two decades. It gained one US patent on April 20, 2010 and two Chinese patents. It is to treat pneumonia.
Furthermore, it is of note that GPHL achieved a sales revenue of RMB 100 billion in 2017 and has 13 new drugs in category 1.1 under development, such as a vaccine treatment for hepatitis B, tumor preventatives and protein-based biological medication.
(Author: Monica Liu; Editors: Simon Haywood, Olivia Yang)